Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada. more
Time Frame | BCTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -16.84% | -0.33% | -1.49% |
1-Month Return | -21.16% | -4.57% | -0.37% |
3-Month Return | -15.1% | -9.96% | 3.89% |
6-Month Return | -52.06% | -5.67% | 9.34% |
1-Year Return | -89.66% | 2.53% | 25.19% |
3-Year Return | -93.86% | -1.43% | 24.7% |
5-Year Return | -94.99% | 34.73% | 85.39% |
10-Year Return | -99.06% | 102.14% | 187.19% |
Jul '20 | Jul '21 | Jul '22 | Jul '23 | Jul '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2020-07-31","value":"-","profit":true},{"date":"2021-07-31","value":"-","profit":true},{"date":"2022-07-31","value":"-","profit":true},{"date":"2023-07-31","value":"-","profit":true},{"date":"2024-07-31","value":"-","profit":true}] |
Cost of Revenue | 13.99K | 15.57K | 15.14K | 15.53K | 82.58K | [{"date":"2020-07-31","value":16.94,"profit":true},{"date":"2021-07-31","value":18.86,"profit":true},{"date":"2022-07-31","value":18.33,"profit":true},{"date":"2023-07-31","value":18.8,"profit":true},{"date":"2024-07-31","value":100,"profit":true}] |
Gross Profit | (13.99K) | (15.57K) | (15.14K) | (15.53K) | (82.58K) | [{"date":"2020-07-31","value":-1399100,"profit":false},{"date":"2021-07-31","value":-1557300,"profit":false},{"date":"2022-07-31","value":-1514100,"profit":false},{"date":"2023-07-31","value":-1552900,"profit":false},{"date":"2024-07-31","value":-8258300,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2020-07-31","value":"-","profit":true},{"date":"2021-07-31","value":"-","profit":true},{"date":"2022-07-31","value":"-","profit":true},{"date":"2023-07-31","value":"-","profit":true},{"date":"2024-07-31","value":"-","profit":true}] |
Operating Expenses | (1.38M) | (3.69M) | (3.39K) | 23.27M | 32.73M | [{"date":"2020-07-31","value":-4.23,"profit":false},{"date":"2021-07-31","value":-11.27,"profit":false},{"date":"2022-07-31","value":-0.01,"profit":false},{"date":"2023-07-31","value":71.11,"profit":true},{"date":"2024-07-31","value":100,"profit":true}] |
Operating Income | 1.38M | 3.69M | (15.29M) | (23.27M) | (32.81M) | [{"date":"2020-07-31","value":37.52,"profit":true},{"date":"2021-07-31","value":100,"profit":true},{"date":"2022-07-31","value":-414.36,"profit":false},{"date":"2023-07-31","value":-630.72,"profit":false},{"date":"2024-07-31","value":-889.16,"profit":false}] |
Total Non-Operating Income/Expense | (108.47K) | (6.89M) | (7.78M) | 3.86M | 28.30M | [{"date":"2020-07-31","value":-0.38,"profit":false},{"date":"2021-07-31","value":-24.33,"profit":false},{"date":"2022-07-31","value":-27.5,"profit":false},{"date":"2023-07-31","value":13.64,"profit":true},{"date":"2024-07-31","value":100,"profit":true}] |
Pre-Tax Income | 1.38M | 3.69M | (11.55M) | (20.30M) | (4.79M) | [{"date":"2020-07-31","value":37.52,"profit":true},{"date":"2021-07-31","value":100,"profit":true},{"date":"2022-07-31","value":-313.03,"profit":false},{"date":"2023-07-31","value":-550.23,"profit":false},{"date":"2024-07-31","value":-129.86,"profit":false}] |
Income Taxes | (72.25K) | 6.58M | 30.73K | (152.62K) | 62.85K | [{"date":"2020-07-31","value":-1.1,"profit":false},{"date":"2021-07-31","value":100,"profit":true},{"date":"2022-07-31","value":0.47,"profit":true},{"date":"2023-07-31","value":-2.32,"profit":false},{"date":"2024-07-31","value":0.95,"profit":true}] |
Income After Taxes | 1.46M | (2.89M) | (11.58M) | (20.15M) | (4.85M) | [{"date":"2020-07-31","value":100,"profit":true},{"date":"2021-07-31","value":-198.7,"profit":false},{"date":"2022-07-31","value":-794.94,"profit":false},{"date":"2023-07-31","value":-1383.15,"profit":false},{"date":"2024-07-31","value":-333.22,"profit":false}] |
Income From Continuous Operations | (4.94M) | (428.33K) | (15.29M) | (20.30M) | (4.93M) | [{"date":"2020-07-31","value":-494422100,"profit":false},{"date":"2021-07-31","value":-42833400,"profit":false},{"date":"2022-07-31","value":-1528894100,"profit":false},{"date":"2023-07-31","value":-2030239400,"profit":false},{"date":"2024-07-31","value":-493154800,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-07-31","value":"-","profit":true},{"date":"2021-07-31","value":"-","profit":true},{"date":"2022-07-31","value":"-","profit":true},{"date":"2023-07-31","value":"-","profit":true},{"date":"2024-07-31","value":"-","profit":true}] |
Net Income | 1.38M | (2.89M) | (11.58M) | (20.30M) | (4.79M) | [{"date":"2020-07-31","value":100,"profit":true},{"date":"2021-07-31","value":-209.07,"profit":false},{"date":"2022-07-31","value":-836.42,"profit":false},{"date":"2023-07-31","value":-1466.35,"profit":false},{"date":"2024-07-31","value":-346.07,"profit":false}] |
EPS (Diluted) | (5.21) | - | (1.90) | (0.99) | (1.17) | [{"date":"2020-07-31","value":-521.44,"profit":false},{"date":"2021-07-31","value":"-","profit":true},{"date":"2022-07-31","value":-190,"profit":false},{"date":"2023-07-31","value":-99,"profit":false},{"date":"2024-07-31","value":-117,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
BCTX | |
---|---|
Cash Ratio | 1.16 |
Current Ratio | 1.65 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BCTX | |
---|---|
ROA (LTM) | -126.11% |
ROE (LTM) | -206.01% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BCTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.64 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.36 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BCTX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 5.78 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Briacell Therapeutics Corp (BCTX) share price today is $0.5369
Yes, Indians can buy shares of Briacell Therapeutics Corp (BCTX) on Vested. To buy Briacell Therapeutics Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BCTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Briacell Therapeutics Corp (BCTX) via the Vested app. You can start investing in Briacell Therapeutics Corp (BCTX) with a minimum investment of $1.
You can invest in shares of Briacell Therapeutics Corp (BCTX) via Vested in three simple steps:
The 52-week high price of Briacell Therapeutics Corp (BCTX) is $5.97. The 52-week low price of Briacell Therapeutics Corp (BCTX) is $0.46.
The price-to-earnings (P/E) ratio of Briacell Therapeutics Corp (BCTX) is
The price-to-book (P/B) ratio of Briacell Therapeutics Corp (BCTX) is 5.78
The dividend yield of Briacell Therapeutics Corp (BCTX) is 0.00%
The market capitalization of Briacell Therapeutics Corp (BCTX) is $24.01M
The stock symbol (or ticker) of Briacell Therapeutics Corp is BCTX